Fig. 5
From: Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers
Clinical validation of ETV6 in uterine serous cancer. a Kaplan–Meier plot for uterine serous patients stratified by ETV6-staining score. Patient samples (N = 31) were divided into two groups based on intensity of ETV6 and positivity in nuclei or cytoplasm (patients with cytoplasmic, negative or weak/medium [score = 1 or 2] nuclear ETV6 staining, N = 20; and patients with strong [score = 3] nuclear ETV6 staining, N = 11). A significant difference in survival was observed between the groups (P = 0.004, log-rank test). The median survival was 2330 days (95% CI: 104–4556 days) for the cytoplasmic or weak nuclear group and 214 days (95% CI: 53–891) for the strong nuclear group. Source data are provided as a Source Data file. b Representative image of immunofluorescence staining on a primary uterine serous tumor. Double staining for ETV6 (green) and cytokeratin (red), shows nuclear localization of ETV6 in tumor cells; DAPI (4′,6-diamidino‐2‐phenylindole): blue. Source data are provided as a Source Data file
